Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Cancer Stage III: early-phase trial registry
1 of 3 indexed Lung Cancer Stage III trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Lung Cancer Stage III: 3 US clinical trials tracked, 1 recruiting.
Lung Cancer Stage III is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Abramson Cancer Center at Penn Medicine, running 1 of these trials.
Enrollment posture brief
Registry condition lung-cancer-stage-iii
OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Lung Cancer Stage III lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lung Cancer Stage III on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Cancer Stage III is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Memorial Sloan Kettering Cancer Center
NCT04991025
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Abramson Cancer Center at Penn Medicine
NCT04305613
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
Wake Forest University Health Sciences
NCT03141359
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Lung Cancer Stage III records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lung Cancer Stage III trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lung Cancer Stage III page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Lung Cancer Stage III trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Abramson Cancer Center at Penn Medicine sponsors the most Lung Cancer Stage III trials on record, review their full trial history before evaluating a specific study. See Abramson Cancer Center at Penn Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Cancer Stage III condition card totals 3 registered trials; most-linked intervention Carboplatin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.